BRIEF-Exelixis announces detailed results from late-stage pivotal trial
Reuters
Oct 20
BRIEF-Exelixis announces detailed results from late-stage pivotal trial
Oct 20 (Reuters) - Exelixis Inc EXEL.O:
EXELIXIS ANNOUNCES DETAILED RESULTS FROM PHASE 3 STELLAR-303 PIVOTAL TRIAL EVALUATING ZANZALINTINIB IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR IN METASTATIC COLORECTAL CANCER PRESENTED AT ESMO 2025 AND PUBLISHED IN THE LANCET
EXELIXIS INC - ZANZALINTINIB WITH ATEZOLIZUMAB IMPROVES MEDIAN OVERALL SURVIVAL TO 10.9 MONTHS
EXELIXIS INC - PLANS NEW DRUG APPLICATION FOR ZANZALINTINIB IN US IN 2025
Source text: ID:nBw8CPxyPa
Further company coverage: EXEL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.